Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Penumbra (PEN)

Penumbra Q3 revenue rises 11.1% to $301.0 million; net income $29.5 million

Positive Impact 3 of 5 earnings Written later

Penumbra reported third-quarter 2024 revenue of $301.0 million, up 11.1% from a year earlier, and GAAP net income of $29.5 million, versus $9.2 million in the same quarter of 2023. It reiterated full-year 2024 revenue guidance of $1,180.0 million to $1,200.0 million and raised the low end of its U.S. thrombectomy growth outlook to 24% to 25%, from 23% to 25%.

Key points

  • Q3 2024 GAAP diluted EPS was $0.75, versus $0.23 a year earlier; non-GAAP diluted EPS was $0.85, versus $0.67.
  • Q3 2024 included $5.0 million in one-time expenses tied to the wind down of the Immersive Healthcare business.
  • Nine-month 2024 GAAP net loss was $19.7 million, including a $76.9 million impairment charge, and the company kept its 2024 revenue guidance unchanged.

The filing

CompanyPenumbra (PEN)
Form8-K, current report
Filed with the SECOct 30, 2024, 4:14 PM ET
Accession number0001321732-24-000116

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.